

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
5 August 2004 (05.08.2004)

PCT

(10) International Publication Number
WO 2004/065589 A1

(51) International Patent Classification⁷:
C12N 5/06,
5/08, A61P 9/00

C12N 5/06,

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): CROISSANT, Jeffrey, D. [US/US]; 12 Seagull Lane, Scituate, MA 02066 (US). YOO, Hee-Won [KR/KR]; B-907, Kungjeon APT, Bangbaebon-dong, Seocho-gu, 137-069 Seoul (KR).

(21) International Application Number:
PCT/KR2003/002898

(22) International Filing Date:
30 December 2003 (30.12.2003)

(74) Agent: LEE, Byung-Hyun; #705, New Seoul Bldg., 828-8, Yeoksam-dong, Gangnam-gu, Seoul 135-080 (KR).

(25) Filing Language:

Korean

(81) Designated States (*national*): JP, US.

(26) Publication Language:

English

(84) Designated States (*regional*): European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

(30) Priority Data:
10-2003-0004565 23 January 2003 (23.01.2003) KR


Published:

— with international search report

(71) Applicant (*for all designated States except US*): ANTEROGEN CO., LTD. [KR/KR]; 399-1, Daebang-dong, Dongjak-gu, 156-811 Seoul (KR).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHOD OF PREPARING CELL FOR TRANSPLANTATION



(57) **Abstract:** The invention features a method of producing cells for transplantation into myocardial tissue of a mammal and a method for treating a disorder using the cells. The method comprises the steps: (a) providing bone marrow stem cells that have not been immortalized; (b) culturing said bone marrow stem cells in a culture medium containing IGF-1 (Insulin-like Growth Factor-I) under conditions that induce said cells to differentiate into cardiomyogenic cells; (c) monitoring the differentiation state of the cells of step (b); and (d) collecting the cells of step (b) when at least about 50 % of said cells are cardiomyogenic cells. According to the method, the highest yield of the cells to be transplanted into mammal cardiac tissue which have the characteristics of cardiomyocyte cell lineage mostly can be obtained. The cells produced as such can be used for treating a disorder characterized by insufficient cardiac function.

WO 2004/065589 A1

BEST AVAILABLE COPY